These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 31969334)

  • 1. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
    Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
    Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression.
    Liu W; Ding Z; Tao Y; Liu S; Jiang M; Yi F; Wang Z; Han Y; Zong H; Li D; Zhu Y; Xie Z; Sang S; Chen X; Miao M; Chen X; Lin W; Zhao Y; Zheng G; Zafereo M; Li G; Wu J; Zha X; Liu Y
    Mol Cancer; 2024 Jul; 23(1):141. PubMed ID: 38982480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.
    Edwards ZC; Trotter EW; Torres-Ayuso P; Chapman P; Wood HM; Nyswaner K; Brognard J
    Cancer Res; 2017 Sep; 77(18):4961-4972. PubMed ID: 28760853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
    Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
    Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.
    Di Agostino S; Valenti F; Sacconi A; Fontemaggi G; Pallocca M; Pulito C; Ganci F; Muti P; Strano S; Blandino G
    Theranostics; 2018; 8(7):1850-1868. PubMed ID: 29556360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
    Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
    Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
    [No Abstract]   [Full Text] [Related]  

  • 10. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
    Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    García-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
    Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
    Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
    Liu C; Sadat SH; Ebisumoto K; Sakai A; Panuganti BA; Ren S; Goto Y; Haft S; Fukusumi T; Ando M; Saito Y; Guo T; Tamayo P; Yeerna H; Kim W; Hubbard J; Sharabi AB; Gutkind JS; Califano JA
    Clin Cancer Res; 2020 Jun; 26(11):2693-2703. PubMed ID: 31932491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
    Dong L; Liu C; Sun H; Wang M; Sun M; Zheng J; Yu X; Shi R; Wang B; Zhou Q; Chen Z; Xing B; Wang Y; Yao X; Mei M; Ren Y; Zhou X
    Cancer Lett; 2024 Jul; 593():216956. PubMed ID: 38735381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
    Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
    Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
    Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.